Digital Pulse Plethysmography: a Sensitive Test of the Pharmacodynamics of Nitrates — Reproducibility and Quantitation of the Technique

Schinz, A; Gottsauner, A.; Schnelle, Karl B.

doi:10.1007/978-3-642-68085-4_17

Cited by 8 publications

(4 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…E Wagner et al: Isosorbide-5-mononitrate kinetics and dynamics digital pulse waves, was obtained by dividing the height of the systolic peak (a) by the height of the dicrotic wave (b) [10]. Changes in venous distensibility were determined by means of venous occlusion plethysmography using the Periflow (Janssen Scientific Instruments, Beerse, Belgium).…”

Section: Methodsmentioning

confidence: 99%

Relationship between pharmacokinetics and hemodynamic tolerance to isosorbide-5-mononitrate

Wagner

Siefert

Trenk

et al. 1990

Eur J Clin Pharmacol

View full text Add to dashboard Cite

Healthy male volunteers received three different dose regimens of a controlled-release form of isosorbide-5-mononitrate (IS-5-MN; 60 mg per tablet). Dose regimen I consisted of a single daily dose of 60 mg given for 5 days. Dose regimen II was started with a dose of 60 mg, followed by 30 mg 12 h later and thereafter every 8 h. The last dose, on the 5th day was again 60 mg. In dose regimen III 60 mg followed by 30 mg 6 h later were administered every day for 5 days. The peripheral arterial and venous effects of IS-5-MN during the first and last dosing interval were followed by changes in the finger pulse curve, standing systolic blood pressure, heart rate, and venous distensibility. Plasma concentrations of IS-5-MN were measured frequently following the first and the last dose. Following dose regimen I all hemodynamic effects produced by the first dose were maintained during the study. The maximal plasma concentrations were about 400 ng/ml and the trough value, lower than 100 ng/ml. Following dose regimen II the hemodynamic effects of IS-5-MN and sublingual glyceroltrinitrate were completely abolished on the 5th day. Trough plasma concentrations were approximately 300 ng/ml during the entire study period. Following dose regimen III pronounced hemodynamic effects were seen on the 1st day. However, a significant attenuation of the hemodynamic effects was measured on the 5th day, when trough plasma concentrations were between 100 and 230 ng/ml.(ABSTRACT TRUNCATED AT 250 WORDS)

show abstract

Section: Methodsmentioning

confidence: 99%

Relationship between pharmacokinetics and hemodynamic tolerance to isosorbide-5-mononitrate

Wagner

Siefert

Trenk

et al. 1990

Eur J Clin Pharmacol

View full text Add to dashboard Cite

show abstract

“…The a/b-ratio of the finger pulse curve was measured using a mechanical pulse pickup system before and 5,169 189-856 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, and 120 minutes as well as 2.5, 3, 3.5, 4, and 6 hours after administration of study medication. A small cuff was fixed around the distal phalanx of the middle finger and inflated to a pressure of 50 mmHg.…”

Section: Hemodynamic Assessmentmentioning

confidence: 99%

Comparison of the Initial Hemodynamic Effects of Immediate‐Release versus Sustained‐Release Isosorbide‐5‐Mononitrate following Single Oral Doses

Trenk

Hinder

Stengele

et al. 2000

The Journal of Clinical Pharma

View full text Add to dashboard Cite

In this double-blind, randomized, placebo-controlled cross-over study, the authors investigated the initial time course of effects of isosorbide-5-mononitrate (IS-5-MN) on hemodynamic parameters in 15 healthy male volunteers after administering a single oral dose of either an immediate-release formulation (IS-5-MN 20 mg) or of a sustained-release formulation (IS-5-MN 50 mg). The latter formulation released 15 mg IS-5-MN immediately, while 35 mg of the dose was sustained release. The onset of effect on the a/b-ratio of the finger pulse curve (20 minutes after administration) and on heart rate following orthostatic challenge (30 minutes) was not different following ingestion of either the immediate-release or the sustained-release formulation. Only the systolic blood pressure following orthostatic challenge was affected earlier after ingestion of the immediate-release form of IS-5-MN (10 vs. 30 minutes). There was no statistically significant difference in the maximum effect on the measured hemodynamic parameters between the two formulations. There was no significant difference with respect to the effect per dose between both of the active treatments (i.e., IS-5-MN 20 mg immediate release and IS-5-MN 50 mg sustained release) within 6 hours after administration. The hemodynamic findings were consistent with the observed rates of the increase of plasma concentrations of IS-5-MN following both formulations. Thus, the administration of the sustained-release formulation of IS-5-MN 50 mg caused similar maximum effects when compared with an immediate-release formulation (20 mg). While the onset of effect of IS-5-MN on the a/b-ratio of the finger pulse curve and on heart rate following orthostasis was similar after administration of either the immediate- or the sustained-release formulation, the onset of effect of the sustained-release formulation on systolic blood pressure orthostasis was determined slightly later. However, the latter difference seems to be of minor clinical relevance.

show abstract

“…Finger pulse curves were measured using a photoelectric tranducer fixed to the distal phalanx of the index finger. The a/b ratio, expressed as the mean of 10 consecutive digital pulse waves, was obtained by dividing the height of the systolic peak (a) by the height of the dicrotic wave (b) (Schinz et al, 1981). Changes in venous distensibility were determined by means of venous occlusion plethysmography using the upper thigh.…”

Section: Smentioning

confidence: 99%

Plasma profile and haemodynamic tolerance to isosorbide‐5‐mononitrate in controlled‐release form.

Jähnchen

1992

Brit J Clinical Pharma

View full text Add to dashboard Cite

1 Plasma concentrations and some haemodynamic parameters known to be affected by nitrates, were monitored in healthy volunteers who received three different dose regimens of isosorbide-5-mononitrate (5-ISMN) over 5 day study periods. 2 No haemodynamic tolerance was found in the 60 mg once-daily dose schedule which produced high plasma concentrations during the daytime but concentrations no greater than 100 ng ml-' at night. In contrast, a dose regimen of 60 mg followed by 30 mg 12 h later and thereafter every 8 h until the fifth day induced complete haemodynamic tolerance. With this dose regimen the minimum plasma concentrations were never below 300 ng ml-1. A significant attenuation of haemodynamic effects was also found with the third dose regimen, 60 mg followed by 30 mg 6 h later for 5 days, which produced minimum plasma concentrations of between 100 ng ml-' to 300 ng ml-,; the degree of attenuation rose as trough plasma concentrations increased.3 In conclusion, 60 mg 5-ISMN in a controlled-release (Durules®) preparation given once daily was the only dose regimen not inducing nitrate tolerance.

show abstract

Digital Pulse Plethysmography: a Sensitive Test of the Pharmacodynamics of Nitrates — Reproducibility and Quantitation of the Technique

Cited by 8 publications

References 2 publications

Relationship between pharmacokinetics and hemodynamic tolerance to isosorbide-5-mononitrate

Relationship between pharmacokinetics and hemodynamic tolerance to isosorbide-5-mononitrate

Comparison of the Initial Hemodynamic Effects of Immediate‐Release versus Sustained‐Release Isosorbide‐5‐Mononitrate following Single Oral Doses

Plasma profile and haemodynamic tolerance to isosorbide‐5‐mononitrate in controlled‐release form.

Contact Info

Product

Resources

About